Rituximab
- PDF / 141,339 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 1 Downloads / 175 Views
1
S
Various toxicities: 4 case reports A retrospective study identified four women [ages not stated] who developed various toxicities following rituximab infusions for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Patient 1 developed chills, fever and hypotension several hours following a rituximab 1g infusion. She was admitted to an ICU and received transient vasopressor support. She subsequently received four 0.5g infusions which were tolerated. Patient 2 received rituximab [dosage not stated] and developed cytomegalovirus colitis and viraemia 1 month later. She was continued with rituximab and was administered ganciclovir. Additionally, she was weaned off her oral immunosuppression; her infection cleared. After 32 months of rituximab therapy [dosage not stated], patient 3 presented with neutropenia and fever which had occurred 3 months after her last dose. At the time of neutropenia, she was also receiving mycophenolate mofetil. She was given granulocyte colony stimulating factors and promptly recovered After 18 months of rituximab therapy [dosage not stated], patient 4 presented with neutropenia and fever which had occurred 4 months after her last dose. She was given granulocyte colony stimulating factors and promptly recovered. Rhee EP, et al. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clinical Journal of the American Society of Nephrology 5: 1394-1400, Aug 2010. Available from: URL: http:// 803039188 dx.doi.org/10.2215/cjn.08821209 - USA
0114-9954/10/1320-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 25 Sep 2010 No. 1320
Data Loading...
